Interpret the Thromboelastography (TEG) results: reaction time (R) >17 min, maximum amplitude (MA) 3.5 mm, LY30 68.6 %, CK 50, CKH 13.7, CRTH 71.2 mm, and CFFH 43.0 mm.

TEG Interpretation: Severe Coagulopathy with Critical Hypofibrinogenemia and Hyperfibrinolysis

This TEG demonstrates a life-threatening coagulopathy characterized by severely prolonged clot initiation (R >17 min), profound hypofibrinogenemia (MA 3.5 mm), and pathologic hyperfibrinolysis (LY30 68.6%), requiring immediate aggressive hemostatic resuscitation with cryoprecipitate/fibrinogen concentrate and antifibrinolytic therapy.

Critical Abnormalities Identified

Clot Initiation (R Time)

• R >17.0 minutes (normal: 5.0-9.1 min) 1
• This represents severe delay in initial clot formation, indicating:
  • Factor deficiency (particularly factors II, V, VII, X)
  • Severe anticoagulation effect
  • Dilutional coagulopathy
• The heparinase assay (CKH R: 13.7 min) shows persistent prolongation even after heparin neutralization, confirming this is NOT primarily heparin-related 1

Clot Strength (Maximum Amplitude)

• MA 3.5 mm (normal: 51.0-67.6 mm) 1
• CRTH MA: 71.2 mm (normal: 53.0-68.9 mm) - paradoxically elevated
• CFFH MA: 43.0 mm (normal: 15.3-34.4 mm) - markedly elevated

Critical interpretation: The standard kaolin MA of 3.5 mm indicates catastrophic loss of clot strength. However, the functional fibrinogen assay (CFFH) showing MA 43.0 mm suggests adequate fibrinogen contribution (correlates with fibrinogen ~1000+ mg/dL based on established correlations) 1. This discrepancy between total MA and fibrinogen-specific MA indicates the primary problem is severe platelet dysfunction or thrombocytopenia, not fibrinogen deficiency as initially suggested.

Fibrinolysis (LY30)

• LY30 68.6% (normal: 0.0-3.2%) 1
• This represents catastrophic hyperfibrinolysis - any LY30 >3% is abnormal, and >4.55% predicts massive transfusion in trauma 2
• 68.6% lysis indicates near-complete clot dissolution within 30 minutes

Clinical Significance & Immediate Management

Hemorrhage Risk

This pattern is incompatible with hemostasis and indicates:

• Active or imminent life-threatening hemorrhage
• Likely massive transfusion requirement (R >4.45 min, LY30 >4.55% both predict MT) 2
• Mortality risk is extremely high - TEG R >6 min alone carries 16-fold increased mortality risk (OR 16,95% CI 5.4-53) 3

Goal-Directed Resuscitation Algorithm

Immediate priorities (in order):

1. Antifibrinolytic therapy - FIRST LINE

   • Tranexamic acid 1g IV bolus immediately
   • LY30 68.6% indicates primary hyperfibrinolytic phenotype requiring urgent fibrinolysis inhibition 2

2. Platelet transfusion

   • MA <60 mm threshold for platelet transfusion 2
   • MA 3.5 mm indicates critical need for multiple platelet units
   • Target: raise MA to >50 mm minimum

3. Plasma transfusion

   • R >4.45 min threshold for plasma 2
   • R >17 min indicates massive plasma requirement
   • Use 1:1:1 ratio (RBC:FFP:platelets) if massive transfusion protocol activated 4

4. Consider fibrinogen products (despite elevated CFFH)

   • Angle <67° threshold for fibrinogen supplementation 2
   • While CFFH suggests adequate fibrinogen, the overall coagulopathy may benefit from additional fibrinogen substrate

Differential Diagnosis Context

This pattern is consistent with:

• Disseminated intravascular coagulation (DIC) - consumptive coagulopathy with secondary hyperfibrinolysis 5
• Acute fibrinolysis syndrome - primary hyperfibrinolytic state
• Severe liver disease/cirrhosis - though typically shows less dramatic hyperfibrinolysis 5
• Massive hemorrhage with dilutional coagulopathy
• Obstetric catastrophe (if applicable) - amniotic fluid embolism, placental abruption 6

Critical Pitfalls to Avoid

1. Do NOT delay antifibrinolytics - LY30 68.6% is incompatible with survival without immediate intervention
2. Do NOT rely on conventional coagulation tests (PT/INR, aPTT) - TEG provides real-time functional assessment that conventional tests miss 4
3. Do NOT assume heparin effect - the CKH assay rules this out
4. Do NOT transfuse RBCs alone - requires balanced resuscitation with plasma, platelets, and antifibrinolytics
5. Monitor repeat TEG every 30-60 minutes during active resuscitation to guide ongoing therapy

Expected Response to Treatment

• LY30 should decrease to <3% with adequate antifibrinolytic therapy
• MA should increase to >50 mm with platelet transfusion
• R time should normalize to <9 min with plasma/factor replacement
• Failure to respond suggests ongoing consumption (DIC) or inadequate source control of hemorrhage

This TEG represents a medical emergency requiring immediate activation of massive transfusion protocol, ICU-level care, and identification/treatment of underlying cause.